Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers
–Funding was co-led by DCVC and Andreessen Horowitz (a16z)– May 30, 2024 09:00 AM Pacific Daylight Time PALO ALTO, Calif.–(BUSINESS WIRE)–Valar Labs, the developer of computational histology AI (CHAI) tests for predicting response to cancer…